<DOC>
	<DOCNO>NCT00086528</DOCNO>
	<brief_summary>The primary objective study follow : - To evaluate safety tolerability XL647 administer orally single dose repeat dos subject solid tumor . The secondary objective study follow : - To evaluate plasma pharmacokinetics XL647 administer orally single dose repeat dos subject solid tumor , - To estimate renal elimination XL647 administer orally single dose subject solid tumor . The exploratory objective study follow : - To assess pharmacodynamic effect XL647 administration plasma peripheral blood cell . In addition , subject may eligible enter Treatment Extension Period . The following information obtain part study : - Long-term safety tolerability XL647 repeat administration , - Tumor response repeat administration XL647 .</brief_summary>
	<brief_title>Safety Pharmacokinetics XL647 Administered Orally Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>The subject histologically confirm malignancy metastatic unresectable , standard curative palliative measure exist longer effective , The subject disease assessable tumor marker , physical , radiologic mean , The subject ≥18 year old , There least 4 week since prior chemotherapy radiation therapy ( 6 week last treatment regimen include BCNU mitomycin C ) , The subject ECOG performance status ≤2 ( Karnofsky &gt; 60 % ) , The subject life expectancy ≥3 month , The subject normal organ marrow function ( hemoglobin &gt; 10g/dL , leukocytes &gt; 3,000/mL , absolute neutrophil count &gt; 1,500/µL , platelet &gt; 100,000/µL , total bilirubin within normal institutional limit normal , AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 time upper limit normal , creatinine within normal limit , The subject capable understanding comply protocol sign informed consent document , Sexually active subject ( male female ) must use accepted method contraception course study , Female subject childbearing potential ( premenopausal ) must negative pregnancy test . The subject chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover AEs due agent administer 4 week earlier , The subject receive another investigational agent within 30 day ( 5.5 halflives ) first dose study drug , The subject know brain metastasis , The subject correct QT interval ( QTc ) &gt; 0.44 second , The subject history allergic reaction attribute aspartame component formulation vehicle , The subject uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement , The subject pregnant nursing , The subject know positive human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Solid Tumors</keyword>
</DOC>